An East Asian Phase I, Multicenter, Open-label, Dose-escalation Study of Oral LDE225 in Patients With Advanced Solid Tumors.

Trial Profile

An East Asian Phase I, Multicenter, Open-label, Dose-escalation Study of Oral LDE225 in Patients With Advanced Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Oct 2016

At a glance

  • Drugs Sonidegib (Primary)
  • Indications Basal cell cancer; Medulloblastoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Novartis
  • Most Recent Events

    • 23 Sep 2016 Results of pooled analysis of this and other three studies on patients and four on volunteers published in the European Journal of Clinical Pharmacology (2016).
    • 20 Apr 2016 Results of PK analysis of BOLT study and pooled analysis of other three studies including this published in the Journal of Clinical Pharmacology
    • 29 Aug 2014 Status changed from active, no longer recruiting to completed, as per ClinicalTrials.gov record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top